The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | What to look forward to at ASH 2022 in the field of Waldenström’s macroglobulinemia
In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights what he is looking forward to at the 2022 ASH Annual Meeting, including updates on next-generation Bruton’s tyrosine kinase (BTK) inhibitors, and the importance of biomarkers in Waldenström’s macroglobulinemia (WM). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
